Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Hims & Hers shares dive on end of weight loss drug shortage
In This Article:
Hims & Hers Health (HIMS) shares nosedive on news from the US Food and Drug Administration (FDA) that the shortage in semaglutide drugs, like Novo Nordisk's (NVO) Ozempic and Wegovy, has been resolved.
Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination with Julie Hyman and Alexandra Canal to discuss what the changing weight loss drug supply dynamics mean for Hims & Hers investors.
To watch more expert insights and analysis on the latest market action, check out more Market Domination here.
This post was written by Naomi Buchanan.
Related Videos
Terms and Privacy Policy